A Smartphone App on Medication Adherence

Medication Adherence Clinical Trial

— App  

Official title:

The Effectiveness of a Smartphone App on Medication Adherence and Psychotic Symptoms and Cognitive Functions in Patients With Schizophrenia

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05892120
• Other study ID #: KMURCT20200096
• Status: Enrolling by invitation
• Start date: June 1, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: May 2023
• Source: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Description:

Schizophrenia is a mental disorder that causes severe functional disabilities and imposes a heavy economic burden. Poor medication adherence is one of the major causes of relapse of psychiatric symptoms in schizophrenic patients. This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: December 31, 2023
• Est. primary completion date: July 25, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• schizophrenia

• aged 20 to 65 years

• able to read traditional Chinese

• owning a smartphone

• currently admitted at a psychiatric day-care center

Exclusion Criteria:

• Intellectually disabled or severe cognitive function impairment (Dementia)

Related Conditions & MeSH terms

• Medication Adherence

Intervention

Behavioral:
• the MedAdhere app
The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study

Locations

Country	Name	City	State
Taiwan	Kaohsiung Medical University	Kaohsiung

Sponsors (1)

Lead Sponsor	Collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	psychiatric symptoms	The positive and negative syndrome scale was used to measure participants' psychiatric symptoms.; Of the 30 items on the scale, seven are positive symptoms, seven are negative symptoms, and 16 are general psychopathology symptoms. Symptom severity for each item is rated according to the anchoring points in the 7-point scale (1 = absent; 7 = extreme) that best describe the symptom (Kay et al., 1987). The PANSS score is the sum of ratings across items, ranging from 7 to 49 for the Positive, Negative Scales, and 16 to 112 and 16 to 112 for the General Psychopathology Scale.	Change from Baseline psychiatric symptoms at 8 weeks
Primary	cognitive functions	The Mini-Mental State Examination was used to measure participants' cognitive functions.; The MMSE consists of 15 questions for assessing the following seven cognitive domains: orientation in time and place, memory registration and recall, attention and calculation, and language. The total MMSE score ranged from 0 to 30, and higher scores indicate better cognitive functions.	Change from Baseline cognitive functions at 8 weeks
Primary	Medication adherence rate	Utilizing cloud-based platforms to compute the medication adherence rate.	Change from Baseline Medication adherence' rate at 8 weeks